Visit to England: What Did We Learn?
We just returned from a brief trip to England, where we met with a client, plus a few friends and colleagues. Over several meetings and meals, three issues consistently came…
Menu
The $25 Coffee Mug
Our recent trip to Stockholm and the Nordic Life Science Days conference was quite enlightening, especially as we publicly discuss drug prices (yet again). One presentation at NLSD by SwedenBio enlightened us on how…
Postcards from Trondheim
I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped…
Dublin Calling
What do companies such as Twitter, Facebook, and Google have in common with Pfizer, Amgen, BioMarin, Alkermes, and Jazz Pharmaceuticals? Dublin. All of them have set up international operations in Dublin, in…
A Rainy Day for Spanish Pharmacists
Yesterday's Financial Times reported that pharmacists in Spain are struggling to continue operating their businesses due to a lack of payment from the Regional governments. “We depend 80 to 90…
GSK gets it
As FiercePharma correctly points out, GSK's Q II report reflects the overall industry trends quite accurately: The rest of Glaxo's report, like the rest of Big Pharma's Q2 results so…
Update: Pain continues to be painful
This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually…
EU Not Jazzed about Fibromyalgia Either
It was recently announced that the EMA has rejected Xyrem for the treatment of fibromyalgia. Interestingly, Xyrem is already approved in Europe for the treatment of narcolepsy with cataplexy. We…
Russian government spurs pharma growth
Earlier this week, Prime Minister Putin announced that the Russian government will invest nearly $4 billion to modernize the pharmaceutical industry in Russia. Of note: Putin said he wanted 90…
Launch evolution across Pharmerging Markets
PharmaPhorum has an excellent analysis on launch evolution across pharmerging markets, such as China, Brazil, Russia, and so forth. A few items of note: 1. The author projects that by…